|
US3400019A
(en)
*
|
1961-12-26 |
1968-09-03 |
Pullman Inc |
Electrode including nonmetallic substrate
|
|
US4816567A
(en)
|
1983-04-08 |
1989-03-28 |
Genentech, Inc. |
Recombinant immunoglobin preparations
|
|
US4518584A
(en)
|
1983-04-15 |
1985-05-21 |
Cetus Corporation |
Human recombinant interleukin-2 muteins
|
|
US5116943A
(en)
|
1985-01-18 |
1992-05-26 |
Cetus Corporation |
Oxidation-resistant muteins of Il-2 and other protein
|
|
US5206344A
(en)
|
1985-06-26 |
1993-04-27 |
Cetus Oncology Corporation |
Interleukin-2 muteins and polymer conjugation thereof
|
|
US4676980A
(en)
|
1985-09-23 |
1987-06-30 |
The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Target specific cross-linked heteroantibodies
|
|
US6548640B1
(en)
|
1986-03-27 |
2003-04-15 |
Btg International Limited |
Altered antibodies
|
|
IL85035A0
(en)
|
1987-01-08 |
1988-06-30 |
Int Genetic Eng |
Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
|
|
US5770701A
(en)
|
1987-10-30 |
1998-06-23 |
American Cyanamid Company |
Process for preparing targeted forms of methyltrithio antitumor agents
|
|
US5606040A
(en)
|
1987-10-30 |
1997-02-25 |
American Cyanamid Company |
Antitumor and antibacterial substituted disulfide derivatives prepared from compounds possessing a methyl-trithio group
|
|
WO1990005144A1
(en)
|
1988-11-11 |
1990-05-17 |
Medical Research Council |
Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors
|
|
DE3920358A1
(de)
|
1989-06-22 |
1991-01-17 |
Behringwerke Ag |
Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
|
|
US5081235A
(en)
|
1989-07-26 |
1992-01-14 |
City Of Hope |
Chimeric anti-cea antibody
|
|
AU6290090A
(en)
|
1989-08-29 |
1991-04-08 |
University Of Southampton |
Bi-or trispecific (fab)3 or (fab)4 conjugates
|
|
CA2026147C
(en)
|
1989-10-25 |
2006-02-07 |
Ravi J. Chari |
Cytotoxic agents comprising maytansinoids and their therapeutic use
|
|
US5208020A
(en)
|
1989-10-25 |
1993-05-04 |
Immunogen Inc. |
Cytotoxic agents comprising maytansinoids and their therapeutic use
|
|
US6075181A
(en)
|
1990-01-12 |
2000-06-13 |
Abgenix, Inc. |
Human antibodies derived from immunized xenomice
|
|
US6150584A
(en)
|
1990-01-12 |
2000-11-21 |
Abgenix, Inc. |
Human antibodies derived from immunized xenomice
|
|
US5770429A
(en)
|
1990-08-29 |
1998-06-23 |
Genpharm International, Inc. |
Transgenic non-human animals capable of producing heterologous antibodies
|
|
WO1992009690A2
(en)
|
1990-12-03 |
1992-06-11 |
Genentech, Inc. |
Enrichment method for variant proteins with altered binding properties
|
|
US5571894A
(en)
|
1991-02-05 |
1996-11-05 |
Ciba-Geigy Corporation |
Recombinant antibodies specific for a growth factor receptor
|
|
DE122004000008I1
(de)
|
1991-06-14 |
2005-06-09 |
Genentech Inc |
Humanisierter Heregulin Antikörper.
|
|
WO1994004679A1
(en)
|
1991-06-14 |
1994-03-03 |
Genentech, Inc. |
Method for making humanized antibodies
|
|
GB9114948D0
(en)
|
1991-07-11 |
1991-08-28 |
Pfizer Ltd |
Process for preparing sertraline intermediates
|
|
FI941572A7
(fi)
|
1991-10-07 |
1994-05-27 |
Oncologix Inc |
Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenete lmä
|
|
WO1993008829A1
(en)
|
1991-11-04 |
1993-05-13 |
The Regents Of The University Of California |
Compositions that mediate killing of hiv-infected cells
|
|
JPH08500962A
(ja)
|
1992-02-06 |
1996-02-06 |
クリエイティブ バイオモレキュルズ，インコーポレイテッド |
癌マーカー用生物合成結合蛋白質
|
|
US5229109A
(en)
|
1992-04-14 |
1993-07-20 |
Board Of Regents, The University Of Texas System |
Low toxicity interleukin-2 analogues for use in immunotherapy
|
|
EP1005870B1
(en)
|
1992-11-13 |
2009-01-21 |
Biogen Idec Inc. |
Therapeutic application of chimeric antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
|
|
US5635483A
(en)
|
1992-12-03 |
1997-06-03 |
Arizona Board Of Regents Acting On Behalf Of Arizona State University |
Tumor inhibiting tetrapeptide bearing modified phenethyl amides
|
|
US5780588A
(en)
|
1993-01-26 |
1998-07-14 |
Arizona Board Of Regents |
Elucidation and synthesis of selected pentapeptides
|
|
US5773001A
(en)
|
1994-06-03 |
1998-06-30 |
American Cyanamid Company |
Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
|
|
US5798100A
(en)
|
1994-07-06 |
1998-08-25 |
Immunomedics, Inc. |
Multi-stage cascade boosting vaccine
|
|
US5731168A
(en)
|
1995-03-01 |
1998-03-24 |
Genentech, Inc. |
Method for making heteromultimeric polypeptides
|
|
US5869046A
(en)
|
1995-04-14 |
1999-02-09 |
Genentech, Inc. |
Altered polypeptides with increased half-life
|
|
US5714586A
(en)
|
1995-06-07 |
1998-02-03 |
American Cyanamid Company |
Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
|
|
US5712374A
(en)
|
1995-06-07 |
1998-01-27 |
American Cyanamid Company |
Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates
|
|
WO1996040210A1
(en)
|
1995-06-07 |
1996-12-19 |
Imclone Systems Incorporated |
Antibody and antibody fragments for inhibiting the growth of tumors
|
|
US7423125B2
(en)
|
1995-08-01 |
2008-09-09 |
Vegenics Limited |
Antibodies to VEGF-C
|
|
FR2757863B1
(fr)
|
1996-12-27 |
1999-03-26 |
Inovat Sarl |
Nouvelles substances a activite biologique, leur procede d'obtention et les compositions en renfermant
|
|
AU751659B2
(en)
|
1997-05-02 |
2002-08-22 |
Genentech Inc. |
A method for making multispecific antibodies having heteromultimeric and common components
|
|
US6610833B1
(en)
|
1997-11-24 |
2003-08-26 |
The Institute For Human Genetics And Biochemistry |
Monoclonal human natural antibodies
|
|
ES2375931T3
(es)
|
1997-12-05 |
2012-03-07 |
The Scripps Research Institute |
Humanización de anticuerpo murino.
|
|
CA2317727C
(en)
|
1998-01-23 |
2013-01-08 |
Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw |
Multipurpose antibody derivatives
|
|
PT2180007E
(pt)
|
1998-04-20 |
2013-11-25 |
Roche Glycart Ag |
Engenharia de glicosilação de anticorpos para melhorar a citotoxicidade celular dependente de anticorpos
|
|
US6737056B1
(en)
|
1999-01-15 |
2004-05-18 |
Genentech, Inc. |
Polypeptide variants with altered effector function
|
|
ES2568899T3
(es)
|
1999-04-09 |
2016-05-05 |
Kyowa Hakko Kirin Co., Ltd. |
Procedimiento para controlar la actividad de una molécula inmunofuncional
|
|
KR20020027490A
(ko)
*
|
1999-07-12 |
2002-04-13 |
제넨테크, 인크. |
Ｃｄ20에 결합하는 길항제를 사용한 외래 항원에 대한면역 반응 차단 방법
|
|
US20030180714A1
(en)
|
1999-12-15 |
2003-09-25 |
Genentech, Inc. |
Shotgun scanning
|
|
PT1242438E
(pt)
|
1999-12-29 |
2007-02-28 |
Immunogen Inc |
Agentes citotóxicos compreendendo dixorrubicinas e daunorrubicinas modificadas e seu uso terapêutico
|
|
SI2857516T1
(sl)
|
2000-04-11 |
2017-09-29 |
Genentech, Inc. |
Multivalentna protitelesa in njihove uporabe
|
|
WO2002009573A2
(en)
|
2000-07-31 |
2002-02-07 |
The Brigham And Women's Hospital, Inc. |
Prognostic classification of endometrial cancer
|
|
US6946292B2
(en)
|
2000-10-06 |
2005-09-20 |
Kyowa Hakko Kogyo Co., Ltd. |
Cells producing antibody compositions with increased antibody dependent cytotoxic activity
|
|
US6596541B2
(en)
|
2000-10-31 |
2003-07-22 |
Regeneron Pharmaceuticals, Inc. |
Methods of modifying eukaryotic cells
|
|
ES2405944T3
(es)
|
2000-11-30 |
2013-06-04 |
Medarex, Inc. |
Ácidos nucleicos que codifican las secuencias de inmunoglobulina humana reorganizadas a partir de ratones transcromoscómicos transgénicos
zadas
|
|
NZ603111A
(en)
|
2001-08-03 |
2014-05-30 |
Roche Glycart Ag |
Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity
|
|
JP2005507870A
(ja)
|
2001-08-13 |
2005-03-24 |
ユニバーシティ・オブ・サザン・カリフォルニア |
低毒性のインターロイキン−２突然変異体
|
|
ES2326964T3
(es)
|
2001-10-25 |
2009-10-22 |
Genentech, Inc. |
Composiciones de glicoproteina.
|
|
EP1454138B1
(en)
|
2001-12-04 |
2012-01-18 |
Merck Patent GmbH |
Immunocytokines with modulated selectivity
|
|
US20040093621A1
(en)
|
2001-12-25 |
2004-05-13 |
Kyowa Hakko Kogyo Co., Ltd |
Antibody composition which specifically binds to CD20
|
|
KR101001243B1
(ko)
|
2001-12-27 |
2010-12-17 |
글리코파이, 인크. |
포유동물-유형 탄수화물 구조의 설계 방법
|
|
US7317091B2
(en)
|
2002-03-01 |
2008-01-08 |
Xencor, Inc. |
Optimized Fc variants
|
|
US20040132101A1
(en)
|
2002-09-27 |
2004-07-08 |
Xencor |
Optimized Fc variants and methods for their generation
|
|
JPWO2003085119A1
(ja)
|
2002-04-09 |
2005-08-11 |
協和醗酵工業株式会社 |
抗体組成物のＦｃγ受容体ＩＩＩａに対する結合活性を高める方法
|
|
US20050031613A1
(en)
|
2002-04-09 |
2005-02-10 |
Kazuyasu Nakamura |
Therapeutic agent for patients having human FcgammaRIIIa
|
|
JPWO2003085118A1
(ja)
|
2002-04-09 |
2005-08-11 |
協和醗酵工業株式会社 |
抗体組成物の製造方法
|
|
AU2003236020B2
(en)
|
2002-04-09 |
2009-03-19 |
Kyowa Hakko Kirin Co., Ltd. |
Cell with depression or deletion of the activity of protein participating in GDP-fucose transport
|
|
BR0309145A
(pt)
|
2002-04-09 |
2005-02-01 |
Kyowa Hakko Kogyo Kk |
Células das quais o genoma é modificado
|
|
CA2488441C
(en)
|
2002-06-03 |
2015-01-27 |
Genentech, Inc. |
Synthetic antibody phage libraries
|
|
WO2004024927A1
(en)
|
2002-09-12 |
2004-03-25 |
Greenovation Biotech Gmbh |
Protein production method
|
|
ES2744275T3
(es)
|
2002-10-17 |
2020-02-24 |
Genmab As |
Anticuerpos monoclonales humanos contra CD20 para su uso en el tratamiento de esclerosis múltiple
|
|
DE60332957D1
(de)
|
2002-12-16 |
2010-07-22 |
Genentech Inc |
Immunoglobulinvarianten und deren verwendungen
|
|
AU2003294912B2
(en)
|
2002-12-20 |
2009-06-04 |
Greenovation Biotech Gmbh |
Production of heterologous glycosylated proteins in bryophyte cells
|
|
WO2004063351A2
(en)
|
2003-01-09 |
2004-07-29 |
Macrogenics, Inc. |
IDENTIFICATION AND ENGINEERING OF ANTIBODIES WITH VARIANT Fc REGIONS AND METHODS OF USING SAME
|
|
WO2004065416A2
(en)
|
2003-01-16 |
2004-08-05 |
Genentech, Inc. |
Synthetic antibody phage libraries
|
|
JP5425365B2
(ja)
|
2003-01-22 |
2014-02-26 |
グリカート バイオテクノロジー アクチェンゲゼルシャフト |
増加したＦｃレセプター結合親和性およびエフェクター機能を有する抗体を作製するための融合構築物およびその使用
|
|
WO2004106381A1
(en)
|
2003-05-31 |
2004-12-09 |
Micromet Ag |
Pharmaceutical compositions comprising bispecific anti-cd3, anti-cd19 antibody constructs for the treatment of b-cell related disorders
|
|
US8076459B2
(en)
|
2003-10-16 |
2011-12-13 |
Micromet Ag |
Multispecfic deimmunized CD3-binders
|
|
JP4653109B2
(ja)
*
|
2003-11-05 |
2011-03-16 |
ロシュ グリクアート アクチェンゲゼルシャフト |
高められたＦｃレセプター結合親和性及びエフェクター機能をもつＣＤ２０抗体
|
|
SG149815A1
(en)
|
2003-11-06 |
2009-02-27 |
Seattle Genetics Inc |
Monomethylvaline compounds capable of conjugation to ligands
|
|
SI1691833T1
(sl)
|
2003-11-28 |
2010-06-30 |
Micromet Ag |
Zmes s polipeptidi
|
|
US7235641B2
(en)
|
2003-12-22 |
2007-06-26 |
Micromet Ag |
Bispecific antibodies
|
|
US7273608B2
(en)
|
2004-03-11 |
2007-09-25 |
City Of Hope |
Humanized anti-CEA T84.66 antibody and uses thereof
|
|
KR101245983B1
(ko)
|
2004-03-31 |
2013-06-28 |
제넨테크, 인크. |
인간화 항-ｔｇｆ-베타 항체
|
|
US7785903B2
(en)
|
2004-04-09 |
2010-08-31 |
Genentech, Inc. |
Variable domain library and uses
|
|
PL1737891T3
(pl)
|
2004-04-13 |
2013-08-30 |
Hoffmann La Roche |
Przeciwciała przeciw selektynie p
|
|
JP5848861B2
(ja)
|
2004-04-20 |
2016-01-27 |
ジェンマブ エー／エスＧｅｎｍａｂ Ａ／Ｓ |
Ｃｄ２０に対するヒトモノクローナル抗体
|
|
EP1753783B1
(en)
|
2004-06-03 |
2014-08-06 |
Novimmune SA |
Anti-cd3 antibodies and methods of use thereof
|
|
TWI380996B
(zh)
|
2004-09-17 |
2013-01-01 |
Hoffmann La Roche |
抗ｏｘ４０ｌ抗體
|
|
TWI487535B
(zh)
|
2004-11-30 |
2015-06-11 |
Centocor Inc |
類鐸受體３（ｔｏｌｌ ｌｉｋｅ ｒｅｃｅｐｔｏｒ３）拮抗劑，方法及用途
|
|
NZ556286A
(en)
|
2005-02-07 |
2010-11-26 |
Glycart Biotechnology Ag |
Antigen binding molecules that bind EGFR, vectors encoding same, and uses thereof
|
|
DK3050963T3
(da)
|
2005-03-31 |
2019-12-09 |
Chugai Pharmaceutical Co Ltd |
Fremgangsmåde til fremstilling af polypeptid ved regulering af arrangement
|
|
US8475794B2
(en)
*
|
2005-04-06 |
2013-07-02 |
Ibc Pharmaceuticals, Inc. |
Combination therapy with anti-CD74 antibodies provides enhanced toxicity to malignancies, Autoimmune disease and other diseases
|
|
WO2006114115A1
(de)
|
2005-04-26 |
2006-11-02 |
Trion Pharma Gmbh |
Kombination von antikörpern mit glukokortikoiden zur behandlung von krebs
|
|
DK2161336T4
(en)
|
2005-05-09 |
2017-04-24 |
Ono Pharmaceutical Co |
Human monoclonal antibodies for programmed death 1 (PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapies
|
|
MX2007013924A
(es)
|
2005-05-09 |
2008-01-28 |
Glycart Biotechnology Ag |
Moleculas que unen antigeno que tienen regiones fc modificadas y union alterada a receptores fc.
|
|
RS54271B1
(sr)
|
2005-07-01 |
2016-02-29 |
E. R. Squibb & Sons, L.L.C. |
Humana monoklonska antitela za ligand programirane smrti 1 (pd-l1)
|
|
EP2500352A1
(en)
|
2005-08-19 |
2012-09-19 |
Abbott Laboratories |
Dual variable domain immunoglobulin and uses thereof
|
|
US7612181B2
(en)
|
2005-08-19 |
2009-11-03 |
Abbott Laboratories |
Dual variable domain immunoglobulin and uses thereof
|
|
JP5373396B2
(ja)
|
2005-08-26 |
2013-12-18 |
ロシュ グリクアート アクチェンゲゼルシャフト |
改変された細胞シグナル活性有する改変抗原結合分子
|
|
WO2007042261A2
(en)
|
2005-10-11 |
2007-04-19 |
Micromet Ag |
Compositions comprising cross-species-specific antibodies and uses thereof
|
|
US8679490B2
(en)
|
2005-11-07 |
2014-03-25 |
Genentech, Inc. |
Binding polypeptides with diversified and consensus VH/VL hypervariable sequences
|
|
WO2007064919A2
(en)
|
2005-12-02 |
2007-06-07 |
Genentech, Inc. |
Binding polypeptides with restricted diversity sequences
|
|
EP1959993B1
(en)
|
2005-12-16 |
2014-11-19 |
IBC Pharmaceuticals, Inc. |
Multivalent immunoglobulin-based bioactive assemblies
|
|
AU2006328882B2
(en)
|
2005-12-21 |
2011-06-16 |
Amgen Research (Munich) Gmbh |
Pharmaceutical antibody compositions with resistance to soluble CEA
|
|
PL1976880T3
(pl)
|
2005-12-21 |
2017-01-31 |
Amgen Research (Munich) Gmbh |
Kompozycje farmaceutyczne odporne na rozpuszczalny cea
|
|
EP1999154B1
(en)
|
2006-03-24 |
2012-10-24 |
Merck Patent GmbH |
Engineered heterodimeric protein domains
|
|
WO2007134050A2
(en)
|
2006-05-09 |
2007-11-22 |
Genentech, Inc. |
Binding polypeptides with optimized scaffolds
|
|
AU2007257692B2
(en)
|
2006-06-12 |
2013-11-14 |
Aptevo Research And Development Llc |
Single-chain multivalent binding proteins with effector function
|
|
EP2035456A1
(en)
|
2006-06-22 |
2009-03-18 |
Novo Nordisk A/S |
Production of bispecific antibodies
|
|
ES2399075T3
(es)
|
2006-08-30 |
2013-03-25 |
Genentech, Inc. |
Anticuerpos multiespecíficos
|
|
DK2066796T3
(da)
|
2006-09-20 |
2011-10-03 |
Mt Biomethan Gmbh |
Fremgangsmåde og indretning til fraskillelse af methan og kuldioxid fra biogas
|
|
CN109456410B
(zh)
|
2007-04-03 |
2022-01-28 |
安进研发（慕尼黑）股份有限公司 |
跨物种特异性CD3-ε结合结构域
|
|
CN103694350B
(zh)
|
2007-04-03 |
2018-04-24 |
安进研发（慕尼黑）股份有限公司 |
跨物种特异性CD3-ε结合结构域
|
|
US20100183615A1
(en)
|
2007-04-03 |
2010-07-22 |
Micromet Ag |
Cross-species-specific bispecific binders
|
|
CN100592373C
(zh)
|
2007-05-25 |
2010-02-24 |
群康科技(深圳)有限公司 |
液晶显示面板驱动装置及其驱动方法
|
|
US8906356B2
(en)
|
2007-11-05 |
2014-12-09 |
Massachusetts Institute Of Technology |
Mutant interleukin-2 (IL-2) polypeptides
|
|
EP2225275A4
(en)
|
2007-11-28 |
2013-04-03 |
Medimmune Llc |
PROTEIN FORMULATION
|
|
US8227577B2
(en)
|
2007-12-21 |
2012-07-24 |
Hoffman-La Roche Inc. |
Bivalent, bispecific antibodies
|
|
US8242247B2
(en)
|
2007-12-21 |
2012-08-14 |
Hoffmann-La Roche Inc. |
Bivalent, bispecific antibodies
|
|
US9266967B2
(en)
|
2007-12-21 |
2016-02-23 |
Hoffmann-La Roche, Inc. |
Bivalent, bispecific antibodies
|
|
US20090162359A1
(en)
|
2007-12-21 |
2009-06-25 |
Christian Klein |
Bivalent, bispecific antibodies
|
|
WO2009089004A1
(en)
|
2008-01-07 |
2009-07-16 |
Amgen Inc. |
Method for making antibody fc-heterodimeric molecules using electrostatic steering effects
|
|
MX2010008786A
(es)
|
2008-02-11 |
2010-12-01 |
Curetech Ltd |
Anticuerpos monoclonales para tratamiento de tumores.
|
|
WO2009114335A2
(en)
|
2008-03-12 |
2009-09-17 |
Merck & Co., Inc. |
Pd-1 binding proteins
|
|
US20090269339A1
(en)
*
|
2008-04-29 |
2009-10-29 |
Genentech, Inc. |
Responses to immunizations in rheumatoid arthritis patients treated with a cd20 antibody
|
|
CN102203125A
(zh)
|
2008-08-25 |
2011-09-28 |
安普利穆尼股份有限公司 |
Pd-1拮抗剂及其使用方法
|
|
HRP20170908T1
(hr)
|
2008-12-09 |
2017-09-22 |
F. Hoffmann - La Roche Ag |
Protutijela anti-pd-l1 i njihova uporaba za poboljšanje funkcije t-stanice
|
|
CA2756244A1
(en)
|
2009-04-02 |
2010-10-07 |
Roche Glycart Ag |
Multispecific antibodies comprising full length antibodies and single chain fab fragments
|
|
ES2537100T3
(es)
|
2009-04-07 |
2015-06-02 |
Roche Glycart Ag |
Anticuerpos biespecíficos trivalentes
|
|
EP2424567B1
(en)
|
2009-04-27 |
2018-11-21 |
OncoMed Pharmaceuticals, Inc. |
Method for making heteromultimeric molecules
|
|
PE20120540A1
(es)
|
2009-05-27 |
2012-05-09 |
Hoffmann La Roche |
Anticuerpos triespecificos o tetraespecificos
|
|
EP2261258A1
(de)
|
2009-06-08 |
2010-12-15 |
Schuler, Gerold |
MCSP-gerichtete scFv-Antikörperfragmente und deren Verwendung
|
|
US9676845B2
(en)
|
2009-06-16 |
2017-06-13 |
Hoffmann-La Roche, Inc. |
Bispecific antigen binding proteins
|
|
US8703132B2
(en)
|
2009-06-18 |
2014-04-22 |
Hoffmann-La Roche, Inc. |
Bispecific, tetravalent antigen binding proteins
|
|
JP5744872B2
(ja)
|
2009-08-31 |
2015-07-08 |
ロシュ グリクアート アーゲー |
親和性成熟ヒト化抗ｃｅａモノクローナル抗体
|
|
US9493578B2
(en)
|
2009-09-02 |
2016-11-15 |
Xencor, Inc. |
Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
|
|
PT2504364T
(pt)
|
2009-11-24 |
2017-11-14 |
Medimmune Ltd |
Agentes de ligação direcionados contra b7-h1
|
|
JP2013512251A
(ja)
|
2009-11-24 |
2013-04-11 |
アンプリミューン、インコーポレーテッド |
Ｐｄ−ｌ１／ｐｄ−ｌ２の同時阻害
|
|
NZ600820A
(en)
|
2009-12-29 |
2014-12-24 |
Emergent Product Dev Seattle |
Heterodimer binding proteins and uses thereof
|
|
AU2011215900A1
(en)
*
|
2010-02-10 |
2012-07-26 |
Immunogen, Inc. |
CD20 antibodies and uses thereof
|
|
AR080793A1
(es)
|
2010-03-26 |
2012-05-09 |
Roche Glycart Ag |
Anticuerpos biespecificos
|
|
US9527926B2
(en)
|
2010-05-14 |
2016-12-27 |
Rinat Neuroscience Corp. |
Heterodimeric proteins and methods for producing and purifying them
|
|
RS59589B1
(sr)
|
2010-11-05 |
2019-12-31 |
Zymeworks Inc |
Dizajniranje stabilnog heterodimernog antitela sa mutacijama u fc domenu
|
|
MX349057B
(es)
|
2010-11-30 |
2017-07-07 |
Chugai Pharmaceutical Co Ltd |
Agente terapeutico que induce citotoxicidad.
|
|
EP2673294B1
(en)
|
2011-02-10 |
2016-04-27 |
Roche Glycart AG |
Mutant interleukin-2 polypeptides
|
|
EP3333193A1
(en)
|
2011-03-02 |
2018-06-13 |
Roche Glycart AG |
Cea antibodies
|
|
KR20160044598A
(ko)
|
2011-03-29 |
2016-04-25 |
로슈 글리카트 아게 |
항체 Fc 변이체
|
|
EA201892619A1
(ru)
|
2011-04-29 |
2019-04-30 |
Роше Гликарт Аг |
Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
|
|
WO2012154530A1
(en)
|
2011-05-06 |
2012-11-15 |
The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Recombinant immunotoxin targeting mesothelin
|
|
WO2012158818A2
(en)
|
2011-05-16 |
2012-11-22 |
Fabion Pharmaceuticals, Inc. |
Multi-specific fab fusion proteins and methods of use
|
|
EA033677B1
(ru)
|
2011-05-21 |
2019-11-15 |
Macrogenics Inc |
Cd3-связывающие молекулы, способные к связыванию с cd3 человека и cd3, не являющимся человеческим
|
|
US20140242081A1
(en)
|
2011-07-18 |
2014-08-28 |
Micromet Ag |
Dosing regimens for treatment of cea-expressing cancers
|
|
TW201326212A
(zh)
|
2011-08-23 |
2013-07-01 |
Roche Glycart Ag |
抗－ｍｃｓｐ抗體
|
|
KR20140048292A
(ko)
|
2011-08-23 |
2014-04-23 |
로슈 글리카트 아게 |
항-mcsp 항체
|
|
PE20141521A1
(es)
|
2011-08-23 |
2014-10-25 |
Roche Glycart Ag |
Moleculas biespecificas de union a antigeno activadoras de celulas t
|
|
ES2686327T3
(es)
|
2011-08-23 |
2018-10-17 |
Roche Glycart Ag |
Moléculas de unión a antígeno biespecíficas
|
|
US20130058936A1
(en)
|
2011-08-23 |
2013-03-07 |
Peter Bruenker |
Bispecific antibodies specific for t-cell activating antigens and a tumor antigen and methods of use
|
|
KR101723273B1
(ko)
|
2011-08-23 |
2017-04-04 |
로슈 글리카트 아게 |
2 개의 ｆａｂ 단편을 포함하는 fc-부재 항체 및 이용 방법
|
|
US20130078250A1
(en)
|
2011-08-23 |
2013-03-28 |
Oliver Ast |
Bispecific t cell activating antigen binding molecules
|
|
EP2578230A1
(en)
|
2011-10-04 |
2013-04-10 |
Trion Pharma Gmbh |
Removal of Tumor Cells from Intraoperative Autologous Blood Salvage
|
|
US10851178B2
(en)
|
2011-10-10 |
2020-12-01 |
Xencor, Inc. |
Heterodimeric human IgG1 polypeptides with isoelectric point modifications
|
|
US20130302274A1
(en)
*
|
2011-11-25 |
2013-11-14 |
Roche Glycart Ag |
Combination therapy
|
|
LT2794905T
(lt)
|
2011-12-20 |
2020-07-10 |
Medimmune, Llc |
Modifikuoti polipeptidai, skirti bispecifinių antikūnų karkasams
|
|
RU2673153C2
(ru)
|
2012-04-20 |
2018-11-22 |
АПТЕВО РИСЁРЧ ЭНД ДИВЕЛОПМЕНТ ЭлЭлСи |
Полипептиды, связывающиеся с cd3
|
|
CA2870821C
(en)
|
2012-04-20 |
2022-06-14 |
Merus B.V. |
Methods and means for the production of ig-like molecules
|
|
CA2915412A1
(en)
|
2012-06-14 |
2013-12-19 |
Therapix Biosciences Ltd. |
Humanized antibodies to cluster of differentiation 3 (cd3)
|
|
EP2895203A4
(en)
|
2012-06-15 |
2016-09-28 |
Imaginab Inc |
ANTIGENBINDING CONSTRUCTS FOR CD3
|
|
US20150203591A1
(en)
|
2012-08-02 |
2015-07-23 |
Regeneron Pharmaceuticals, Inc. |
Mutivalent antigen-binding proteins
|
|
AR092044A1
(es)
|
2012-08-07 |
2015-03-18 |
Roche Glycart Ag |
Inmunoterapia mejorada
|
|
AU2013302696B9
(en)
|
2012-08-14 |
2018-08-09 |
Ibc Pharmaceuticals, Inc. |
T-cell redirecting bispecific antibodies for treatment of disease
|
|
JOP20200236A1
(ar)
|
2012-09-21 |
2017-06-16 |
Regeneron Pharma |
الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
|
|
MX2015003616A
(es)
|
2012-10-08 |
2015-06-05 |
Roche Glycart Ag |
Anticuerpos sin fc que comprenden dos fragmentos fab y metodos de uso.
|
|
UY35148A
(es)
|
2012-11-21 |
2014-05-30 |
Amgen Inc |
Immunoglobulinas heterodiméricas
|
|
US10487155B2
(en)
|
2013-01-14 |
2019-11-26 |
Xencor, Inc. |
Heterodimeric proteins
|
|
US10131710B2
(en)
|
2013-01-14 |
2018-11-20 |
Xencor, Inc. |
Optimized antibody variable regions
|
|
US10968276B2
(en)
|
2013-03-12 |
2021-04-06 |
Xencor, Inc. |
Optimized anti-CD3 variable regions
|
|
US9605084B2
(en)
|
2013-03-15 |
2017-03-28 |
Xencor, Inc. |
Heterodimeric proteins
|
|
DK2943511T3
(da)
|
2013-01-14 |
2019-10-21 |
Xencor Inc |
Nye heterodimeriske proteiner
|
|
US9701759B2
(en)
|
2013-01-14 |
2017-07-11 |
Xencor, Inc. |
Heterodimeric proteins
|
|
EP2953974B1
(en)
|
2013-02-05 |
2017-12-20 |
EngMab Sàrl |
Bispecific antibodies against cd3epsilon and bcma
|
|
JO3529B1
(ar)
|
2013-02-08 |
2020-07-05 |
Amgen Res Munich Gmbh |
مضاد التصاق خلايا الدم البيض من أجل التخفيف من الاثار السلبية الممكنة الناتجة عن مجالات ارتباط cd3- المحدد
|
|
MX2015010843A
(es)
|
2013-02-26 |
2016-04-04 |
Roche Glycart Ag |
Moleculas biespecificas de union al antigeno que activan celulas t.
|
|
PT2961771T
(pt)
|
2013-02-26 |
2020-02-28 |
Roche Glycart Ag |
Moléculas de ligação ao antigénio biespecíficas para ativação das células t, específicas para cd3 e cea
|
|
CN105143270B
(zh)
|
2013-02-26 |
2019-11-12 |
罗切格利卡特公司 |
双特异性t细胞活化抗原结合分子
|
|
EP3721902A1
(en)
|
2013-03-14 |
2020-10-14 |
The Scripps Research Institute |
Targeting agent antibody conjugates and uses thereof
|
|
US20140302037A1
(en)
|
2013-03-15 |
2014-10-09 |
Amgen Inc. |
BISPECIFIC-Fc MOLECULES
|
|
US10858417B2
(en)
|
2013-03-15 |
2020-12-08 |
Xencor, Inc. |
Heterodimeric proteins
|
|
TW201501724A
(zh)
|
2013-03-15 |
2015-01-16 |
Glaxosmithkline Ip No 2 Ltd |
低濃度抗體調配物
|
|
EP3587448B1
(en)
|
2013-03-15 |
2021-05-19 |
Xencor, Inc. |
Heterodimeric proteins
|
|
EP2789630A1
(en)
|
2013-04-09 |
2014-10-15 |
EngMab AG |
Bispecific antibodies against CD3e and ROR1
|
|
MX370829B
(es)
*
|
2013-05-02 |
2020-01-08 |
Hoffmann La Roche |
Uso de un anticuerpo para cd20 afucosilado con un conjugado de anticuerpo para cd22-fármaco.
|
|
KR101824311B1
(ko)
*
|
2013-05-02 |
2018-01-31 |
에프. 호프만-라 로슈 아게 |
어푸코실화된 CD20 항체와 CD79b 항체-약물 접합체의 병용 요법
|
|
EP3004164A1
(en)
|
2013-05-28 |
2016-04-13 |
Numab AG |
Novel antibodies
|
|
MX373245B
(es)
|
2013-07-05 |
2020-05-11 |
Genmab As |
Anticuerpos cd3 humanizados o quiméricos.
|
|
JP2017501157A
(ja)
*
|
2013-12-17 |
2017-01-12 |
ジェネンテック， インコーポレイテッド |
Ｐｄ−１軸結合アンタゴニスト及び抗ｃｄ２０抗体を使用してがんを治療する方法
|
|
EP3736292B1
(en)
|
2013-12-17 |
2024-05-08 |
Genentech, Inc. |
Anti-cd3 antibodies and methods of use
|
|
JP6841656B2
(ja)
|
2013-12-17 |
2021-03-10 |
ジェネンテック， インコーポレイテッド |
Ｐｄ−１軸結合アンタゴニスト及びタキサンを使用する癌の治療方法
|
|
JP6557664B2
(ja)
|
2014-01-06 |
2019-08-07 |
エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ |
一価の血液脳関門シャトルモジュール
|
|
UA117289C2
(uk)
|
2014-04-02 |
2018-07-10 |
Ф. Хоффманн-Ля Рош Аг |
Мультиспецифічне антитіло
|
|
US20170073415A1
(en)
|
2014-05-12 |
2017-03-16 |
Numab Ag |
Novel multispecific molecules and novel treatment methods based on such multispecific molecules
|
|
CN106459201A
(zh)
|
2014-05-28 |
2017-02-22 |
豪夫迈·罗氏有限公司 |
结合人和食蟹猴CD3ε的抗体
|
|
BR112017001579A2
(pt)
|
2014-07-25 |
2017-11-21 |
Cytomx Therapeutics Inc |
anticorpos anti-cd3, anticorpos anti-cd3 ativáveis, anticorpos anti-cd3 multiespecíficos, anticorpos anti-cd3 ativáveis multiespecíficos e métodos de uso dos mesmos
|
|
CR20170032A
(es)
|
2014-08-04 |
2017-04-04 |
Hoffmann La Roche |
Moleculas biespecíficas de unión a antígeno activadoras de células t
|
|
EP2982692A1
(en)
|
2014-08-04 |
2016-02-10 |
EngMab AG |
Bispecific antibodies against CD3epsilon and BCMA
|
|
EP2982693A1
(en)
|
2014-08-07 |
2016-02-10 |
Affimed Therapeutics AG |
CD3 binding domain
|
|
WO2016019969A1
(en)
|
2014-08-08 |
2016-02-11 |
Ludwig-Maximilians-Universität München |
Subcutaneously administered bispecific antibodies for use in the treatment of cancer
|
|
MY193723A
(en)
|
2014-08-29 |
2022-10-27 |
Hoffmann La Roche |
Combination therapy of tumor-targeted il-2 variant immunocytokines and antibodies against human pd-l1
|
|
WO2016036678A1
(en)
|
2014-09-02 |
2016-03-10 |
Medimmune, Llc |
Formulations of bispecific antibodies
|
|
MA40764A
(fr)
|
2014-09-26 |
2017-08-01 |
Chugai Pharmaceutical Co Ltd |
Agent thérapeutique induisant une cytotoxicité
|
|
ES2850325T3
(es)
|
2014-10-09 |
2021-08-27 |
Engmab Sarl |
Anticuerpos biespecíficos contra CD3epsilon y ROR1
|
|
US20170306044A1
(en)
|
2014-10-09 |
2017-10-26 |
Engmab Ag |
Bispecific antibodies against cd3epsilon and ror1 for use in the treatment of ovarian cancer
|
|
PL3221357T3
(pl)
|
2014-11-20 |
2020-11-02 |
F. Hoffmann-La Roche Ag |
Wspólne łańcuchy lekkie i sposoby zastosowania
|
|
MX2017006571A
(es)
|
2014-11-20 |
2017-09-29 |
Hoffmann La Roche |
Moleculas de union a antigeno biespecificas activadoras de celulas t.
|
|
EP3023437A1
(en)
|
2014-11-20 |
2016-05-25 |
EngMab AG |
Bispecific antibodies against CD3epsilon and BCMA
|
|
EP3029068A1
(en)
|
2014-12-03 |
2016-06-08 |
EngMab AG |
Bispecific antibodies against CD3epsilon and BCMA for use in the treatment of diseases
|
|
EP3778640A1
(en)
|
2015-05-01 |
2021-02-17 |
Genentech, Inc. |
Masked anti-cd3 antibodies and methods of use
|
|
US10323094B2
(en)
|
2015-06-16 |
2019-06-18 |
Genentech, Inc. |
Humanized and affinity matured antibodies to FcRH5 and methods of use
|
|
HRP20200390T1
(hr)
|
2015-08-03 |
2020-06-12 |
Engmab Sàrl |
Monoklonska antitijela protiv humanog antigena starenja b stanica (bcma)
|
|
MA43025A
(fr)
|
2015-10-02 |
2021-05-26 |
Hoffmann La Roche |
Molécules bispécifiques de liaison à l'antigène activant les lymphocytes t anti-ceaxcd3
|
|
WO2017055318A1
(en)
|
2015-10-02 |
2017-04-06 |
F. Hoffmann-La Roche Ag |
Cd33xcd3 bispecific t cell activating antigen binding molecules
|
|
EP3356417A1
(en)
|
2015-10-02 |
2018-08-08 |
H. Hoffnabb-La Roche Ag |
Bispecific t cell activating antigen binding molecules binding mesothelin and cd3
|
|
EP3356409A2
(en)
|
2015-10-02 |
2018-08-08 |
H. Hoffnabb-La Roche Ag |
Bispecific t cell activating antigen binding molecules
|
|
WO2017055314A1
(en)
|
2015-10-02 |
2017-04-06 |
F. Hoffmann-La Roche Ag |
Bispecific anti-cd19xcd3 t cell activating antigen binding molecules
|
|
EP4026848A1
(en)
|
2015-12-09 |
2022-07-13 |
F. Hoffmann-La Roche AG |
Type ii anti-cd20 antibody for reducing the cytokine release syndrome
|
|
WO2018093821A1
(en)
|
2016-11-15 |
2018-05-24 |
Genentech, Inc. |
Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies
|